Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
First received: November 2, 1999
Last updated: May 21, 2012
Last Verified: May 2012
History of Changes
The purpose of this study is to evaluate the safety of giving indinavir and rifabutin at the
same time (simultaneously) vs 4 hours apart (staggered) to HIV-positive and HIV-negative
It is important to determine which medications for HIV-associated diseases, such as Mycobacterium avium complex (MAC) disease, can be given safely and effectively with anti-HIV drugs. Indinavir and rifabutin have been given simultaneously in the past with good results. This study seeks to examine if staggering the doses will make the 2 drugs more effective. HIV-negative volunteers are used in this study to examine the effect of rifabutin on indinavir and the effect of staggered rifabutin doses. The effect of rifabutin on the drug activity of indinavir is evaluated in HIV-positive patients.
Drug : Indinavir sulfate
Drug : Rifabutin
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Steady-State Pharmacokinetic Interaction Study of Indinavir and Rifabutin|
Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):
|Study Completion Date:||October 2000|
Currently, rifabutin is the only rifamycin that can be administered with indinavir. ACTG 365
is the first formal study of the pharmacokinetics of this dosing combination regimen in HIV
seropositive patients. It is hypothesized that staggered administration of rifabutin and
indinavir might minimize their pharmacokinetic interaction. If the intestinal tract plays a
significant role in the presystemic clearance of rifabutin, the inhibitory activity of
indinavir on rifabutin could depend on either luminal concentrations of indinavir, systematic
concentrations of indinavir, or both. If luminal concentrations are important, then the
interaction between these 2 drugs will be maximal when administered simultaneously, and
minimal when their oral administration is staggered. Finally, since indinavir has a half-life
of 1.8 hours, its effects on rifabutin's systematic clearance may be much less when
administration of these drugs is staggered by 4 hours as compared with simultaneous
administration with rifabutin. If the interaction on rifabutin is minimized, then the
rifabutin levels may be suboptimal for treatment of tuberculosis in patients who are not
administered the 2 drugs simultaneously. It is, therefore, important to define the magnitude
of the effect of staggered vs simultaneous drug administration in order to clarify dose and
regimen recommendations in HIV-infected patients with tuberculosis who also require protease
Study Arm A is a multiple-dose, 3-period, sequential study in 18 evaluable HIV-infected indinavir-naive male and female volunteers [AS PER AMENDMENT 11/16/98: Arm A will be assessed in 18 evaluable HIV-seronegative patients]. Patients receive 3 different treatments consisting of 14 days of administration: rifabutin alone (Period IA); indinavir plus rifabutin (Period IIA); and indinavir plus rifabutin (Period IIIA). Study Arm B is a multiple-dose, 2-period, sequential study in 10 evaluable HIV-infected male and female volunteers. Patients receive 2 different treatments, each consisting of 14 days of administration; indinavir alone (Period IB); and indinavir plus rifabutin (Period IIB). Patients on both arms take each dose of their study medications with water. [AS PER AMENDMENT 8/8/97: Patients treated on Arm A are randomized, following Period IA therapy, to Period IIA or IIIA therapy for 14 days, then are crossed over to the alternate regimen for 14 days.] [AS PER AMENDMENT 4/17/98: After completion of therapy on Arm A or B, patients continue therapy with indinavir alone for 7 days.] [AS PER AMENDMENT 11/16/98: The final 7 days of indinavir dosing has been eliminated for patients on Arm A. Also per this amendment, to ensure compliance, Arm A patients' rifabutin supply will be dispensed in containers fitted with an electronic monitoring cap device.]
|Ages Eligible for Study:||18 Years to 60 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
You may be eligible for this study if you:
- Are HIV-positive or HIV-negative.
- Agree to practice abstinence or to use birth control during the study.
- Have an active opportunistic (HIV-associated) disease or other disease requiring medication within 14 days of study entry.
- Have a history of illness that might put you at risk if given either of the study drugs.
- Have had any severe allergies to any substance in the past.
- Have a history of kidney stones.
- Have a medical condition, or problems with use of alcohol or drugs, which would keep you from completing the study.
- Have had tuberculosis and have never been treated for it.
- Are pregnant or breast-feeding.
- Are taking certain medications.
You will not be eligible for this study if you:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000877
Locations Show More
|United States, California|
|Univ of Southern California / LA County USC Med Ctr|
|Los Angeles, California, United States, 900331079|
|Univ of Southern California / LA County USC Med Cntr|
|Los Angeles, California, United States, 90033|
|United States, Colorado|
|Univ of Colorado Health Sciences Ctr|
|Denver, Colorado, United States, 80262|
|United States, Florida|
|Univ of Miami School of Medicine|
|Miami, Florida, United States, 331361013|
|United States, Indiana|
|Indiana Univ Hosp|
|Indianapolis, Indiana, United States, 462025250|
|United States, Maryland|
|Johns Hopkins Hosp|
|Baltimore, Maryland, United States, 21287|
|United States, New York|
|Bellevue Hosp / New York Univ Med Ctr|
|New York, New York, United States, 10016|
|Cornell Univ Med Ctr|
|New York, New York, United States, 10021|
Sponsors and CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)
|Study Chair:||Charles Flexner|
|Study Chair:||Constance Benson|
|Study Chair:||Judith Currier|
|Responsible Party:||National Institute of Allergy and Infectious Diseases (NIAID)|
|ClinicalTrials.gov Identifier:||NCT00000877 History of Changes|
|Other Study ID Numbers:||ACTG 365|
|Study First Received:||November 2, 1999|
|Last Updated:||May 21, 2012|
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):Rifabutin
Drug Therapy, Combination
HIV Protease Inhibitors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on May 24, 2020
This information is provided by ClinicalTrials.gov.